文献速递妇科

早期3级子宫内膜样子宫内膜腺癌的综合分子特征分析

Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma.
PubMed 文献 · Gynecol Oncol · 2024-08-09

本研究纳入两家机构的46例IB期3级子宫内膜样子宫内膜腺癌患者,采用免疫组化及全外显子测序进行ProMisE分类、突变特征及常见突变基因分析。结果显示肿瘤分子异质性大,9例(19.6%)复发,POLE亚组无复发,SBS5突变特征与高复发风险相关。

要点

  • 46例IB期3级子宫内膜样子宫内膜腺癌中,9例(19.6%)复发,其中5例(55.6%)为腹腔外转移。
  • ProMisE分类:POLE突变10例(21.7%),MMR缺陷18例(39.1%),p53异常6例(13.0%),p53野生型12例(26.1%)。
  • POLE亚组无复发;6例复发患者均具有SBS5突变特征。

核心结论

  • 尽管组织学、分期和分级相同,该队列肿瘤在分子层面呈现高度异质性。
  • 突变特征SBS5与高复发风险相关。
  • 进一步细化子宫内膜癌分类可能有助于更精确的患者分层和个体化治疗。

研究设计与样本

  • 纳入两家机构IB期3级子宫内膜样子宫内膜腺癌患者46例,辅助治疗各异。
  • 对存档FFPE组织切片进行免疫组化和全外显子测序以确定ProMisE分类,使用Personal Cancer Genome Reporter进行体细胞变异注释,基于COSMIC单碱基替换突变特征生成突变特征。

主要发现

  • 9例(19.6%)复发,其中5例(55.6%)为腹腔外疾病。
  • ProMisE分类:POLE突变10例(21.7%),MMR缺陷18例(39.1%),p53异常6例(13.0%),p53野生型12例(26.1%);POLE亚组无复发。
  • 38例中鉴定出优势突变特征:SBS5 17例(44.7%),SBS15或SBS44 10例(26.3%),SBS10a或SBS10b 7例(18.4%),SBS14 3例(7.9%),SBS40 1例(2.6%);6例复发患者均具有SBS5特征。
  • 常见突变基因包括ARID1A(30例,65%)、PTEN(28例,61%)、MUC16(27例,59%)、PIK3CA(25例,54%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The treatment for stage IB grade 3 endometrioid endometrial adenocarcinoma is challenging with variable practice. Molecular characterization may help identify adjuvant therapy strategies beyond stage. We aimed to better understand the molecular features of these tumors by characterizing them by ProMisE classification, mutational signature, and commonly mutated genes. METHODS: Patients with stage IB grade 3 EEC at two institutions were included. Immunohistochemistry and whole exome sequencing were performed on archival FFPE tissue sections to determine ProMisE classification. Personal Cancer Genome Reporter was used for somatic variant annotation, and mutational signatures were generated based on COSMIC single base substitution mutational signatures. RESULTS: 46 patients were included with variable adjuvant treatment. Nine patients recurred (19.6%), most with extra-abdominal disease (n = 5, or 55.6%). 10 had POLE mutations (21.7%), 18 were MMR deficient (39.1%), 6 had abnormal p53 (13.0%), and 12 were p53 wildtype (26.1%). There were no recurrences in the POLE subgroup. A dominant mutational signature was identified in 38 patients: 17 SBS5 signature (44.7%), 10 SBS15 or SBS44 signature (26.3%), 7 SBS10a or SBS10b signature (18.4%), 3 SBS14 signature (7.9%), and 1 SBS40 signature (2.6%). The six patients that recurred had a SBS5 signature. Frequently mutated genes included ARID1A (n = 30, 65%), PTEN (n = 28, 61%), MUC16 (n = 27, 59%), and PIK3CA (n = 25, 54%). CONCLUSIONS: This comprehensive evaluation found a molecularly diverse cohort of tumors, despite the same histology, stage and grade. Mutational signature SBS5 correlated with a high risk of recurrence. Further refining of endometrial cancer classification may enable more precise patient stratification and personalized treatment approaches.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Cun HT, Bernard L, Lande KT, et al. Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma. Gynecol Oncol. 2024. PMID: 39126895. doi:10.1016/j.ygyno.2024.07.677

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。